X
[{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostar Pharma Announces First Patient Enrolled for Phase 1 Study of Utidelone Capsule (UTD2)--The World's First Oral Epothilone Anti-Cancer Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approved Utidelone Injectable (UTD1) Phase 2\/3 Multi-National Clinical Trial for Non-Small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biostar Pharma Gets FDA Clearance for Phase 2 Study of Utidelone in HER2- Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Beijing Biostar Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
UTD1 (utidelone) is an investigational tubulin inhibitor, given intravenously in combination with capecitabine for its potential efficacy in patients with HER2-negative breast cancer brain metastases.
Lead Product(s):
Utidelone,Capecitabine
Therapeutic Area: Oncology
Product Name: UTD1
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 05, 2024
Details:
UTD1 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of breast cancer brain metastasis.
Lead Product(s):
Utidelone,Bevacizumab ,Etoposide
Therapeutic Area: Oncology
Product Name: UTD1
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 29, 2024
Details:
UTD2 (utidelone) is the only approved innovative microtubule inhibitor developed using synthetic biology technology. It is being evaluated for the treatment of gastric cancer.
Lead Product(s):
Utidelone
Therapeutic Area: Oncology
Product Name: UTD2
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 21, 2024
Details:
UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor, which is investigated for the treatment of advanced solid tumor patients in the US.
Lead Product(s):
Utidelone
Therapeutic Area: Oncology
Product Name: UTD1
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 15, 2023
Details:
UTD2 (utidelone capsule) is the first oral epothilone microtubule inhibitor and which is investigated for the treatment of advanced solid tumor patients in the US.
Lead Product(s):
Utidelone
Therapeutic Area: Oncology
Product Name: UTD2
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 12, 2023